



Medrobotics® Corporation Receives FDA Clearance for Flex® Robotic System for Scarfree™ Colorectal Procedures

Company Now Cleared to Market Flex® Robotic System in U.S. as a Platform Technology for Otolaryngology and Colorectal Surgeries

FOR IMMEDIATE RELEASE

RAYNHAM, Mass., May. 8, 2017- Medrobotics Corp., a medical robotics company, announced today it has received FDA regulatory clearance to market the Flex® Robotic System for colorectal procedures in the United States. Medrobotics is the first and only company to offer minimally invasive, steerable and shapeable robotic products for colorectal procedures in the U.S. The Flex® Robotic System is the world's first robotic surgical platform to offer Scarfree™ access to hard-to-reach anatomy in otolaryngology and colorectal procedures. This provides surgeons treatment options that may not be possible with straight, rigid instruments.

"The human gastrointestinal system is full of twists and turns, and rigid surgical robots were not designed to operate in that environment. The Flex® Robotic System was. Two years ago Medrobotics started revolutionizing treatment in the head and neck in the U.S. We can now begin doing that in colorectal procedures," said CEO Samuel Straface, Ph.D. "American hospitals, surgeons and patients will be able to enjoy the benefits of the world's only flexible, surgical robotic platform. It will easily integrate into hospitals due to its mobility and short learning curve."

"The Flex® Robotic System offers the promise to treat select colorectal patients transanally with a more consistent and an easier approach because it overcomes the limits of straight surgical instrumentation," said Dr. Alessio Pigazzi, Professor of Surgery at the University of California, Irvine. "Medrobotics is ushering in the first of a new generation of shapeable and steerable robotic surgical systems that offer the potential to reduce the invasiveness of surgical procedures for more patients," added Pigazzi.

The minimally invasive Flex® Robotic System offers surgeons the unique ability to navigate complex anatomy through a single, small entry point to operate in difficult-to-reach places. Today, access is gained through the mouth and anus. In future applications, access may be obtained through other natural orifices such as the vagina, or through small incisions in the abdomen. Medrobotics is developing new surgical applications for its core platform technology in the areas of general surgery, gynecology, and urology, among others. These new applications are not yet cleared for use in the U.S.

The award-winning Flex® Robotic System has been widely recognized for advances in surgical robotic technology, including Best-in-Show at the 2016 Medical Design Excellence Awards



(MDEA) and a Best New Product at the 2017 Edison Awards. Medrobotics' Flex® Robotic System was designed to provide an affordable, easy-to-use and highly mobile robot-assisted surgical platform for hospitals and surgeons seeking to provide minimally-invasive treatment options to the broadest number of patients. Minimally invasive surgery has demonstrated advantages for patients and providers, such as shorter hospital stays and faster recovery times.

About Medrobotics

Medrobotics Corporation (www.Medrobotics.com) is a privately funded medical device company headquartered in Raynham, Massachusetts. It manufactures and markets the Flex® Robotic System, the world's first robotic surgical platform with a steerable and shapeable robotic scope. The Flex® Robotic System offers surgeons the unique ability to navigate complex anatomy through a single, small entry point while operating in hard-to-reach anatomical locations that might otherwise be inaccessible with straight, rigid surgical tools. The Company's vision is to provide more patients with access to minimally invasive surgery. Medrobotics received its initial FDA clearance for the Flex® Robotic System in July 2015, and the CE mark in March 2014.

Media Contact:
Kevin Knight
(214) 732-9392
kknightpr@gmail.com